Join Our Growing Team: Part-Qualified Patent Attorney, Physics & Engineering
News, Team news, Careers
19/03/2025
Are you a Part-Qualified Patent Attorney looking to take your career to the next level? Secerna LLP is excited to announce an exceptional opportunity to join our dynamic Physics and Engineering team. We're seeking a talented and ambitious individual to build upon their existing patent experience in a supportive and collaborative environment, working at the forefront of technological innovation.
Read more
Global IP Filings Show Strengthening: WIPO Report Signals Innovation Growth
Industry news, News
18/03/2025
A year of economic uncertainty appears to have given way to renewed confidence in the world of intellectual property, according to figures released today by the World Intellectual Property Organization (WIPO). After a dip in 2023, the organisation’s key registries have seen a marked uptick in patent, trade mark, and design applications, suggesting that global innovation is once again on the rise.
Read more
A to Z: Drugs in Highlight: O is for OZEMPIC®
News, A to Z Feature
13/03/2025
This series continues to explore the fascinating world of pharmaceuticals. Next up is MAVIRET® (from AbbVie), also sold under the brand name MAVYRET®, uses a combination of glecaprevir and pibrentasvir for the treatment of chronic hepatitis C infection.
Read more
Unlocking Innovation: The Latest on the UK Patent Box Scheme
Industry news, News
10/03/2025
At Secerna, we understand the critical role intellectual property (IP) plays in fostering a robust innovation ecosystem. Government incentive programs like the Patent Box offer significant tax advantages specifically designed to encourage research and development (R&D) activities. This article provides a comprehensive overview of the latest developments in the Patent Box scheme and its potential benefits for your business, helping you unlock tax savings and fuel a culture of innovation.
Read more
A to Z: Drugs in Highlight: N is for NILEMDO®
News, A to Z Feature
07/03/2025
This series continues to explore the fascinating world of pharmaceuticals. Next up is MAVIRET® (from AbbVie), also sold under the brand name MAVYRET®, uses a combination of glecaprevir and pibrentasvir for the treatment of chronic hepatitis C infection.
Read more
Secerna attending NEPIC Cluster Connect 2025
Events, Team news
06/03/2025
Secerna LLP is pleased to announce our participation in the NEPIC Cluster Connect event, taking place at the Wilton Centre on March 13th, 2025. This event presents a valuable opportunity for NEPIC members to connect, network, and discuss the latest industry developments.
Read more